Citigroup Inc Black Diamond Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 28,805 shares of BDTX stock, worth $62,794. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,805

Previous 8,163 252.87%

Holding current value

$62,794

Previous $38,000 228.95%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.2 - $6.58 $86,696 - $135,824	20,642 Added 252.87%	28,805 $125,000
Q2 2024 Aug 12, 2024	SELL	$4.65 - $7.39 $484,939 - $770,688	-104,288 Reduced 92.74%	8,163 $38,000
Q1 2024 May 10, 2024	BUY	$2.67 - $5.74 $155,733 - $334,796	58,327 Added 107.77%	112,451 $570,000
Q4 2023 Feb 09, 2024	SELL	$1.77 - $3.03 $12,786 - $21,888	-7,224 Reduced 11.78%	54,124 $152,000
Q3 2023 Nov 09, 2023	BUY	$2.87 - $4.99 $176,068 - $306,126	61,348 New	61,348 $176,000
Q4 2022 Feb 09, 2023	SELL	$1.27 - $2.51 $556 - $1,099	-438 Reduced 76.44%	135 $0
Q3 2022 Nov 10, 2022	SELL	$1.68 - $4.01 $808 - $1,928	-481 Reduced 45.64%	573 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.5 - $3.63 $1,362 - $3,296	-908 Reduced 46.28%	1,054 $3,000
Q1 2022 May 12, 2022	SELL	$2.66 - $5.61 $13,124 - $27,679	-4,934 Reduced 71.55%	1,962 $5,000
Q4 2021 Feb 10, 2022	SELL	$5.18 - $8.48 $217,570 - $356,176	-42,002 Reduced 85.9%	6,896 $37,000
Q3 2021 Nov 10, 2021	BUY	$8.46 - $12.42 $413,677 - $607,313	48,898 New	48,898 $414,000

Others Institutions Holding BDTX

# of Institutions

117

Shares Held

48.8M

Call Options Held

1.84M

Put Options Held

1.93M

View Full List

About Black Diamond Therapeutics, Inc.

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $79.2M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

More about BDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account